The tumor growth volume inhibition rates (TGI) on the 7th, 14th, and 18th days were 7.68%, 53.16%, 39.36% (TLzmab group), 47.28%, 86.80%, and 92.09% (SLBZD+TLzmab group), respectively, indicating that SLBZD can achieve more ideal and lasting therapeutic effects in PD-1 monoclonal antibody immunotherapy (P<0.001); The tumor weight inhibition rates (%) at 18 days were 34.11% in the TLzmab group and 73.00% in the SLBZD+TLzmab group, respectively (p<0.001). Here, PDCD1 is linked to neoplasm.